CTOs on the Move

Alabama Mentor

www.mnw.net

 
Alabama Mentor LLC is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.mnw.net
  • 2900 McGehee Rd
    Montgomery, AL USA 36111
  • Phone: 334.280.3330

Executives

Name Title Contact Details

Similar Companies

Latino Health Institute

Latino Health Institute is a Brockton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MEDZONE

MEDZONE Inc. is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tru-Tain Inc

Tru-Tain Inc is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joint Commission Resources

Joint Commission Resources is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.